First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes: an exploratory analysis of immune biomarkers
Van Rampelbergh J, Achenbach P, Leslie RD, et al.
BMC Med. Pub. online 21 Jun 2024.
Leggi